BIENAIME JEAN JACQUES 4

What Happened
Director Jean-Jacques Bienaime reported two open-market purchases (Form 4 code P) of Ascendis Pharma (ASND) common stock on 2026-05-26. He acquired 200 shares at a weighted-average price of $236.24 (≈ $47,247) and another 200 shares at a weighted-average price of $239.37 (≈ $47,874), for a combined cost of roughly $95,121. These were purchases (insider acquiring shares) rather than sales.

Key Details

• Transaction date: 2026-05-26; Form 4 filed: 2026-05-27 (timely filing).
• Trades: 200 shares @ $236.24 (reported weighted average; actual prices ranged $235.93–$236.54) and 200 shares @ $239.37 (reported weighted average; actual prices ranged $239.245–$239.490).
• Total shares purchased: 400; total reported value: ≈ $95,121.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes: F1 and F2 indicate the reported prices are weighted averages and give the per-transaction price ranges; the filer will provide per-price breakdowns on request.
• Transaction code: P = Purchase (open-market/private purchase).

Context
Insider purchases are often watched by retail investors as one signal that an insider chose to increase ownership, but filings do not state the insider's motive. This filing reports straightforward open-market purchases (no option exercises, awards, gifts, or tax-withhold actions involved). The Form 4 was filed the next day, which is within typical reporting deadlines.